Lake Street Capital Initiates Coverage on Novogen (NASDAQ:KZIA)

Analysts at Lake Street Capital initiated coverage on shares of Novogen (NASDAQ:KZIA) in a research report issued on Thursday. The firm set a “buy” rating and a $32.00 price target on the stock. Lake Street Capital’s price target indicates a potential upside of 178.26% from the company’s current price.

A number of other equities research analysts also recently issued reports on KZIA. Weiss Ratings restated a “sell (d-)” rating on shares of Novogen in a research report on Tuesday, April 21st. Laidlaw initiated coverage on Novogen in a research report on Wednesday, April 15th. They set a “buy” rating and a $25.00 target price on the stock. Finally, Wall Street Zen downgraded Novogen from a “buy” rating to a “hold” rating in a research report on Sunday, March 8th. Four analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $23.75.

Novogen Stock Performance

Shares of KZIA opened at $11.50 on Thursday. The company’s fifty day moving average is $11.49 and its 200 day moving average is $9.23. Novogen has a fifty-two week low of $4.86 and a fifty-two week high of $17.40.

Novogen (NASDAQ:KZIA) last issued its quarterly earnings data on Saturday, February 14th. The company reported ($1.34) EPS for the quarter. The business had revenue of $4.89 million for the quarter. As a group, sell-side analysts anticipate that Novogen will post -0.01 earnings per share for the current year.

Novogen Company Profile

Novogen (NASDAQ:KZIA) is a clinical-stage biotechnology company focused on the discovery and development of novel small-molecule therapeutics for the treatment of cancer. The company’s pipeline includes GDC-0084, a brain-penetrant phosphoinositide 3-kinase (PI3K) inhibitor in Phase II development for glioblastoma, as well as Cantrixil, an orally bioavailable small molecule designed to target treatment-resistant ovarian cancer stem cells. Novogen’s research efforts leverage structure-based drug design to optimize selectivity and pharmacokinetic profiles, seeking to address high-unmet medical needs in oncology.

Founded in Australia and now headquartered in New York City, Novogen maintains research facilities in Perth and collaborates with academic institutions and contract research organizations worldwide.